
Karuna Therapeutics KRTX
Annual report 2023
added 02-22-2024
Karuna Therapeutics Accounts Payables 2011-2026 | KRTX
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Karuna Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.78 M | 2.38 M | 1.94 M | 865 K | 547 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.78 M | 547 K | 2.5 M |
Quarterly Accounts Payables Karuna Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.94 M | 1.1 M | 476 K | 2.38 M | 15.7 M | 3.92 M | 1.48 M | 1.94 M | 1.99 M | 1.97 M | 1.3 M | 865 K | 865 K | 865 K | 865 K | 547 K | 547 K | 547 K | 547 K | 269 K | 269 K | 269 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.7 M | 269 K | 1.89 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Xeris Pharmaceuticals
XERS
|
3.08 M | $ 6.03 | -1.55 % | $ 885 M | ||
|
I-Mab
IMAB
|
570 M | - | - | $ 866 M | ||
|
UroGen Pharma Ltd.
URGN
|
12.1 M | $ 19.2 | -11.52 % | $ 554 M | ||
|
uniQure N.V.
QURE
|
5.17 M | $ 10.89 | -30.36 % | $ 530 M | ||
|
GT Biopharma
GTBP
|
748 K | $ 0.47 | -2.41 % | $ 892 K | ||
|
Adverum Biotechnologies
ADVM
|
1.61 M | - | - | $ 86.2 M | ||
|
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | ||
|
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M | ||
|
AgeX Therapeutics
AGE
|
1.41 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | ||
|
Agenus
AGEN
|
61.4 M | $ 3.36 | 0.86 % | $ 1.2 M | ||
|
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M | ||
|
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | ||
|
Agios Pharmaceuticals
AGIO
|
18.4 M | $ 29.16 | -3.54 % | $ 1.69 B | ||
|
Advaxis
ADXS
|
6.08 M | - | -9.65 % | $ 45.9 M | ||
|
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | ||
|
Alector
ALEC
|
1.69 M | $ 2.19 | -9.77 % | $ 226 M | ||
|
Allena Pharmaceuticals
ALNA
|
1.03 M | - | 3.16 % | $ 1.9 M | ||
|
Aileron Therapeutics
ALRN
|
911 K | - | 10.36 % | $ 9.8 M | ||
|
Altimmune
ALT
|
211 K | $ 4.21 | -2.32 % | $ 299 M | ||
|
AlloVir
ALVR
|
247 K | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | ||
|
Amarin Corporation plc
AMRN
|
45.4 M | $ 13.98 | 1.27 % | $ 5.7 B | ||
|
AbbVie
ABBV
|
3.59 B | $ 233.57 | 0.64 % | $ 413 B | ||
|
Blueprint Medicines Corporation
BPMC
|
6.79 M | - | - | $ 8.14 B | ||
|
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | ||
|
AIM ImmunoTech
AIM
|
377 K | $ 0.8 | -11.6 % | $ 38.5 M | ||
|
Aptorum Group Limited
APM
|
3.24 M | $ 0.83 | 5.37 % | $ 4.53 M | ||
|
Apellis Pharmaceuticals
APLS
|
56.8 M | $ 20.67 | -1.38 % | $ 2.61 B |